Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mannkind Corp (NQ: MNKD ) 6.490 +0.070 (+1.09%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Mannkind Corp < Previous 1 2 Next > Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference September 30, 2024 Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham... Via Newsfile More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®) September 30, 2024 From MannKind Via GlobeNewswire MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease September 18, 2024 From MannKind Via GlobeNewswire MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference September 10, 2024 From MannKind Via GlobeNewswire MannKind to Present at Upcoming Conferences August 27, 2024 From MannKind Via GlobeNewswire Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board August 14, 2024 From MannKind Via GlobeNewswire MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update August 07, 2024 Conference Call to Begin Today at 9:00 a.m. (ET) From MannKind Via GlobeNewswire MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease July 31, 2024 From MannKind Via GlobeNewswire MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024 July 30, 2024 From MannKind Via GlobeNewswire INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions June 22, 2024 From MannKind Via GlobeNewswire Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions June 05, 2024 From MannKind Via GlobeNewswire MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix May 29, 2024 From MannKind Via GlobeNewswire MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update May 08, 2024 Conference Call to Begin Today at 5:00 p.m. (ET) From MannKind Via GlobeNewswire MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease May 06, 2024 From MannKind Via GlobeNewswire MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024 May 01, 2024 From MannKind Via GlobeNewswire MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases April 30, 2024 From MannKind Via GlobeNewswire MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease April 29, 2024 From MannKind Via GlobeNewswire MannKind Repays Certain Debt Obligations April 03, 2024 From MannKind Via GlobeNewswire MannKind Announces CFO Transition March 26, 2024 From MannKind Via GlobeNewswire INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps March 11, 2024 From MannKind Via GlobeNewswire MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 March 05, 2024 Dr. Hirsch to present meal challenge results when switching from multiple daily injections (MDI) or insulin pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder) From MannKind Via GlobeNewswire MannKind Corporation Announces Participation at Upcoming Conferences March 04, 2024 From MannKind Via GlobeNewswire MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update February 27, 2024 Conference Call to Begin Today at 5:00 p.m. (ET) From MannKind Via GlobeNewswire MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 February 20, 2024 From MannKind Via GlobeNewswire MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® February 15, 2024 From MannKind Via GlobeNewswire MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million January 02, 2024 From MannKind Via GlobeNewswire MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference December 28, 2023 From MannKind Via GlobeNewswire MannKind Corporation Reports 2023 Third Quarter Financial Results November 07, 2023 From MannKind Via GlobeNewswire MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes November 06, 2023 From MannKind Via GlobeNewswire MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023 October 31, 2023 From MannKind Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.